Oppenheimer Reiterates Outperform Rating on Neurocrine Bio. (NBIX)

January 16, 2025 10:01 AM EST Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $192.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login